LTP·01learntopeptide
Longevity & bioregulatorsEvidence D3 cited

Pinealon

aka Pinealon bioregulator · Glu-Asp-Arg · EDR peptide

Pinealon is a synthetic tripeptide composed of glutamic acid, aspartic acid, and arginine (Glu-Asp-Arg, or EDR). Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Pinealon is designed as a bioregulator peptide targeting the pineal gland. The pineal gland plays a central role in circadian rhythm regulation through melatonin synthesis. Pinealon is proposed to normalise pineal gland function by modulating gene expression related to melatonin production, potentially supporting sleep quality, circadian rhythm integrity, and neuroprotection. As a short peptide, it is theorised to penetrate cells and interact with DNA to restore age-related decline in pineal function. Evidence remains limited to preclinical studies.

Molecular wt
418.40g/mol
Formula
C15H26N6O8
CAS
175175-23-2
Half-life
2 h
estimated
Tmax
1 h
Route
Oral or subcutaneous
PubChem
10273502

Sequence

One-letter3 residues

EDR

Three-letter

Glu-Asp-Arg

Read this before quoting the sequence
Synthetic tripeptide (the 'EDR peptide'). PubChem CID 10273502 lists 'pinealon', 'Glu-Asp-Arg' and 'L-Glutamyl-L-aspartyl-L-arginine' as synonyms of the same structure.
Source ↗

Mechanism of action

Pinealon (EDR) is proposed to interact with DNA sequences in pineal gland cells, modulating transcription of genes involved in melatonin biosynthesis, including those encoding arylalkylamine N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT). According to Khavinson bioregulation theory, the tripeptide can penetrate cell membranes and nuclear envelopes due to its small size, directly influencing chromatin condensation and gene accessibility in pinealocytes. This may restore melatonin production capacity that declines with age.

What the evidence actually shows

Grade D

Evidence for Pinealon is limited primarily to in vitro and animal studies conducted by Khavinson research group. Preclinical data suggests the EDR peptide can influence gene expression in brain tissue and may have neuroprotective properties in cell culture models of oxidative stress. No rigorous human clinical trials have been published in internationally peer-reviewed journals.

Regulatory status

Status
Not approved as a medicine by FDA or EMA; no marketing authorisation identified in any jurisdiction.
Clinical stage
No registered clinical trials of pinealon found on ClinicalTrials.gov.
Source ↗

Pharmacokinetics

Half-life
2 h
Tmax
1 h
Absorption
subcutaneous
Elimination
renal
Washout
2 days
Low-confidence pharmacokinetics
These figures are recorded as estimated rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Handling and storage

No compound-specific stability data exists
No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Pinealon has no approved label anywhere that could be located. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

References (3)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
storage, reconstitution, regulatory.wada, halfLife

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Longevity & bioregulators

Acein
A research peptide that inhibits connective tissue growth factor (CCN2/CTGF), a key mediator of tissue fibrosis. Targets the fundamental fibrotic pathway involved in organ aging and disease.
Carnosine
A naturally occurring dipeptide (beta-alanine + histidine) with potent anti-glycation, antioxidant, and pH-buffering properties. Acts as an AGE inhibitor, preventing cross-linking of proteins that accelerates tissue aging.
Cortagen
Cortagen is a short synthetic bioregulator peptide developed by Professor Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target the adrenal cortex, supporting the regulation of cortisol production and adrenal gland function. Bioregulator peptides are based on the concept that short peptide sequences derived from or mimicking endogenous tissue-specific peptides can restore gene expression patterns in aging or damaged tissues. Cortagen is proposed to normalise adrenal cortex function by interacting with DNA and modulating transcription of genes involved in steroidogenesis. While the bioregulator concept has theoretical appeal, the evidence base consists primarily of preclinical studies and observational reports from Russian clinical practice.